Erythromelalgia Treatment Market: Why Does a Genetically Identified Disease Still Have No Approved Targeted Drug?
The erythromelalgia treatment market — therapies for a rare neurovascular pain disorder characterized by episodic burning pain, redness, and elevated skin temperature in the extremities, frequently linked to gain-of-function mutations in sodium channel genes — remains a small but steadily growing niche within rare disease pharmaceuticals, with the Erythromelalgia Treatment Market...
0 Commenti 0 condivisioni 2 Views 0 Anteprima